scPharmaceuticals Inc.

NasdaqGS:SCPH Stock Report

Market Cap: US$221.6m

scPharmaceuticals Valuation

Is SCPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SCPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SCPH ($4.46) is trading below our estimate of fair value ($93.55)

Significantly Below Fair Value: SCPH is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SCPH?

Other financial metrics that can be useful for relative valuation.

SCPH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue9.3x
Enterprise Value/EBITDA-3.7x
PEG Ration/a

Price to Sales Ratio vs Peers

How does SCPH's PS Ratio compare to its peers?

The above table shows the PS ratio for SCPH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average14.9x
AMLX Amylyx Pharmaceuticals
1.2x-78.7%US$345.2m
ETST Earth Science Tech
2.3xn/aUS$42.4m
AVDL Avadel Pharmaceuticals
13.1x30.6%US$1.2b
GSTK Growth Stalk Holdings
43xn/aUS$25.1m
SCPH scPharmaceuticals
9.3x45.3%US$221.6m

Price-To-Sales vs Peers: SCPH is good value based on its Price-To-Sales Ratio (9.3x) compared to the peer average (22.3x).


Price to Earnings Ratio vs Industry

How does SCPH's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.5%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.5%
n/an/an/a
No more companies

Price-To-Sales vs Industry: SCPH is expensive based on its Price-To-Sales Ratio (9.3x) compared to the US Pharmaceuticals industry average (2.9x).


Price to Sales Ratio vs Fair Ratio

What is SCPH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SCPH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio9.3x
Fair PS Ratio9.4x

Price-To-Sales vs Fair Ratio: SCPH is good value based on its Price-To-Sales Ratio (9.3x) compared to the estimated Fair Price-To-Sales Ratio (9.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SCPH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$4.46
US$19.17
+329.7%
16.1%US$25.00US$16.00n/a6
Oct ’25US$4.21
US$19.17
+355.3%
16.1%US$25.00US$16.00n/a6
Sep ’25US$5.09
US$19.17
+276.6%
16.1%US$25.00US$16.00n/a6
Aug ’25US$4.79
US$19.50
+307.1%
16.7%US$25.00US$16.00n/a6
Jul ’25US$4.32
US$19.50
+351.4%
16.7%US$25.00US$16.00n/a6
Jun ’25US$3.91
US$19.50
+398.7%
16.7%US$25.00US$16.00n/a6
May ’25US$4.54
US$19.50
+329.5%
16.7%US$25.00US$16.00n/a6
Apr ’25US$4.85
US$19.50
+302.1%
16.7%US$25.00US$16.00n/a6
Mar ’25US$6.12
US$18.83
+207.7%
16.3%US$25.00US$16.00n/a6
Feb ’25US$5.09
US$18.67
+266.7%
16.8%US$25.00US$16.00n/a6
Jan ’25US$6.27
US$18.67
+197.7%
16.8%US$25.00US$16.00n/a6
Dec ’24US$5.49
US$18.67
+240.0%
16.8%US$25.00US$16.00n/a6
Nov ’24US$5.23
US$19.33
+269.7%
15.1%US$25.00US$16.00n/a6
Oct ’24US$7.12
US$19.33
+171.5%
15.1%US$25.00US$16.00US$4.216
Sep ’24US$7.47
US$19.20
+157.0%
16.6%US$25.00US$16.00US$5.095
Aug ’24US$8.31
US$19.20
+131.0%
16.6%US$25.00US$16.00US$4.795
Jul ’24US$10.19
US$19.20
+88.4%
16.6%US$25.00US$16.00US$4.325
Jun ’24US$11.00
US$19.20
+74.5%
16.6%US$25.00US$16.00US$3.915
May ’24US$9.73
US$16.80
+72.7%
26.5%US$25.00US$13.00US$4.545
Apr ’24US$9.07
US$16.80
+85.2%
26.5%US$25.00US$13.00US$4.855
Mar ’24US$7.84
US$16.60
+111.7%
27.6%US$25.00US$13.00US$6.125
Feb ’24US$6.84
US$16.60
+142.7%
27.6%US$25.00US$13.00US$5.095
Jan ’24US$7.17
US$16.40
+128.7%
29.0%US$25.00US$12.00US$6.275
Dec ’23US$7.12
US$16.40
+130.3%
29.0%US$25.00US$12.00US$5.495
Nov ’23US$5.47
US$13.25
+142.2%
11.2%US$15.00US$11.00US$5.234
Oct ’23US$6.52
US$10.33
+58.5%
35.6%US$15.00US$6.00US$7.123

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies